Drug Trial Radar · NCT00148798
Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX)
Last checked: Nov 20, 2026Latest source record: Jun 25, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,861
Actual
Start
Oct 2004
Primary completion
Jul 2007
Study completion May 2012
Sponsor
- Lead sponsor
- Merck KGaA, Darmstadt, GermanyIndustry
- Sponsor type
- Industry
- First posted
- Sep 8, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this trial is to investigate the efficacy of cetuximab in combination with chemotherapy in comparison to chemotherapy alone in patients with advanced non small cell lung cancer who did not received prior chemotherapy. Overall survival will be taken as primary measure of efficacy.
Conditions
- Non Small Cell Lung Cancer (NSCLC)
Interventions
cetuximab + cisplatin + vinorelbineDrug
cetuximab given as an intravenous (i.v.) infusion every week (400mg/m\^2 initial dose and 250mg/m\^2 subsequent doses) until progressive disease (PD) + cisplatin 80mg/m\^2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m\^2 i.v. infusion on days 1 and 8 of each 3-week cycle.
cisplatin + vinorelbineDrug
cisplatin 80mg/m\^2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m\^2 i.v. infusion on days 1 and 8 of each 3-week cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival Time (OS)Time frame: Time from randomisation to death or last day known to be alive, reported between day of first patient randomised, Oct 2004, until cut-off date 18 Jul 2007
Locations
118 sites in 28 countries. Site status is shown where the registry gives one.
Research Site
Buenos Aires, Argentina
Research Site
Córdoba, Argentina
Research Site
Adelaide, Australia
Research Site
Melbourne, Australia
Research Site
Randwick, Australia
Research Site
Sydney, Australia
Research Site
Wodonga, Australia
Research Site
Vienna, Austria
Research Site
Brussels, Belgium
Research Site
Charleroi, Belgium
Research Site
Liège, Belgium
Research Site
Porto Alegre, Brazil
Research Site
São Paulo, Brazil
Research Site
Pleven, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Stara Zagora, Bulgaria
Research Site
Veliko Tarnovo, Bulgaria
Research Site
Antofagasta, Chile
Research Site
Santiago, Chile
Research Site
Brno, Czechia
Research Site
Ostrava, Czechia
Research Site
Pilsen, Czechia
Research Site
Prague, Czechia
Research Site
Brest, France
Research Site
Caen, France
Research Site
Grenoble, France
Research Site
Marseille, France
Research Site
Paris, France
Research Site
Poitiers, France
Research Site
Rennes, France
Research Site
Rouen, France
Research Site
Strasbourg, France
Research Site
Augsburg, Germany
Research Site
Berlin, Germany
Research Site
Cologne, Germany
Research Site
Essen, Germany
Research Site
Freiburg im Breisgau, Germany
Research Site
Gauting, Germany
Research Site
Göttingen, Germany
Research Site
Großhansdorf, Germany
Showing 40 of 118 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.